

BioRestorative Therapies, Inc.  
Form SC 13D/A  
September 30, 2016  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13D  
(Amendment No. 2)\*  
Under the Securities Exchange Act of 1934

BIORESTORATIVE THERAPIES, INC.  
(Name of Issuer)

Common Stock, par value \$0.001 per share  
(Title of Class of Securities)

090655101  
(CUSIP Number)

with a copy to:  
Christopher Henry  
Lowenstein Sandler LLP  
1251 Avenue of the Americas, 17th Floor  
New York, New York 10020  
(212) 419-5840

John M. Desmarais  
230 Park Avenue  
New York, New York 10169  
(212) 351-3420

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

September 26, 2016  
(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), (f) or (g), check the following box [  ].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 090655101

- Names of Reporting Persons. I.R.S.
1. Identification Nos. of Above Persons (entities only):  
John M. Desmarais  
Check the Appropriate
  2. Box if a (a) Member of a Group  
(b)
  3. SEC Use Only
  4. Source of Funds (See Instructions): PF
  5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  
Not Applicable
  6. Citizenship or Place of Organization: United States

Number of	7. Sole Voting Power:	1,766,111 *
Shares Beneficially Owned by	8. Shared Voting Power:	40,000 *
Each Reporting Person With	9. Sole Dispositive Power:	1,766,111*
	10. Shared Dispositive Power:	40,000 *

11. Aggregate Amount Beneficially Owned by Each Reporting Person: 1,806,111 \*
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): Not Applicable
13. Percent of Class Represented by Amount in Row (11): 32.8%\*
14. Type of Reporting Person (See Instructions): IN

\* Based upon the information contained in BioRestorative Therapies, Inc.'s (the "Issuer") Proxy Statement filed with the Securities and Exchange Commission on September 8, 2016, there were 4,150,294 shares of the Issuer's common stock, par value \$0.001 per share (the "Shares"), issued and outstanding as of August 26, 2016.

This Amendment No. 2 to Schedule 13D reflects the aggregate number of Shares beneficially owned by John M. Desmarais (the "Reporting Person") and includes (i) 455,000 Shares owned directly by the Reporting Person; (ii) 125,000 Shares underlying a warrant held by the Reporting Person with an exercise price of \$5.00 per Share and an expiration date of November 17, 2020; (iii) 250,000 Shares underlying a warrant held by the Reporting Person with an exercise price of \$5.00 per Share and an expiration date of March 18, 2021; (iv) 444,444 Shares underlying a warrant held by the Reporting Person with an exercise price of \$4.50 per Share and an expiration date of November 18, 2017; (v) 400,000 Shares underlying a warrant held by the Reporting Person with an exercise price of \$5.00 per Share and an expiration date of March 18, 2018; (vi) 40,000 Shares underlying a warrant held by a trust for the benefit of the Reporting Person's immediate family, for which the Reporting Person and his spouse are trustees, with an exercise price of \$4.00 per Share and an expiration date of June 30, 2021; (vii) 80,000 Shares underlying a warrant held by the Reporting Person with an exercise price of \$4.00 per Share and an expiration date of September 26, 2021 (the foregoing warrants being referred to collectively as the "Warrants"); and (viii) 11,667 Shares underlying an option held by the Reporting Person with an exercise price of \$3.73 per Share and an expiration date of June 10, 2026 (the "Option"). As a result of the foregoing, as of the filing date of this Amendment No. 2 to Schedule 13D, the Reporting Person may be deemed to beneficially own 1,806,111 Shares, or 32.8% of the Shares issued and outstanding as of August 26, 2016. Percent of class assumes the exercise of all of the Warrants and the Option held by the Reporting Person for the acquisition of 1,351,111 Shares.

---

Item 1. Security and Issuer.

This Amendment No. 2 amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on November 30, 2015, as previously amended by Amendment No. 1, dated March 18, 2016.

The classes of securities to which this Schedule 13D relates are: (a) common stock, par value \$0.001 per share (the "Shares"), of BioRestorative Therapies, Inc. (the "Issuer"); and (b) Shares underlying warrants held by the Reporting Person with exercise prices ranging between \$4.00 and \$5.00 per Share (together with the Shares, the "Securities"). The Issuer's principal executive offices are located at 40 Marcus Drive, Suite One, Melville, New York 11747. The Issuer's Shares are quoted on the OTCQB market under the symbol "BRTX".

Item 2. Identity and Background.

(a) This Amendment No. 2 to Schedule 13D is being filed by John M. Desmarais (the "Reporting Person"), an individual.

The Reporting Person directly possesses the sole power to vote and the sole power to direct the disposition of 1,766,111 Shares. The Reporting Person has shared power to vote and direct the disposition of 40,000 Shares.

(b) The Reporting Person's principal office is: Desmarais LLP, 230 Park Avenue, New York, New York 10169.

(c) The Reporting Person's principal occupation is: attorney and founding partner of Desmarais LLP, a law firm specializing in Intellectual Property Law.

(d) – (e) During the last five years, the Reporting Person, has not been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Reporting Person is a citizen of the United States. Desmarais LLP is a New York limited liability partnership.

Item 3. Source and Amount of Funds or Other Consideration.

On September 26, 2016, the Issuer entered into a subscription agreement (the "Subscription Agreement") with the Reporting Person for the sale of units (the "Units") consisting of (i) 80,000 Shares; and (ii) a five year warrant to purchase 80,000 Shares at an exercise price of \$4.00 per Share. The Securities purchased by the Reporting Person were purchased with funds from the Reporting Person's personal bank account. The aggregate amount of funds used in making the purchases reported on this Amendment No. 2 to Schedule 13D was \$240,000. In consideration of the purchase of Units pursuant to the Subscription Agreement, the Issuer extended the expiration dates of warrants, dated March 18, 2016, held by the Reporting Person for the purchase of 444,444 and 400,000 Shares, respectively, for a period of one year from November 18, 2016 and March 18, 2017, respectively, to November 18, 2017 and March 18, 2018, respectively.

---

Item 4. Purpose of Transaction.

All of the Securities beneficially owned by the Reporting Person are held for investment purposes.

The Reporting Person does not have any present plan or proposal which relates to or would result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D, except as set forth herein or as set forth in the public reports filed by the Issuer with the SEC; however, on December 1, 2015, the Reporting Person was appointed to the board of directors of the Issuer (the "Board"). As a member of the Board, the Reporting Person will be involved in deliberations and discussions on various issues affecting the Issuer, which could include, from time to time, matters set forth in subparagraphs (b) - (j) of Item 4 of Schedule 13D.

The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to investment in the Issuer as he deems appropriate including, without limitation, making proposals to the Issuer concerning changes to the capitalization, ownership structure or operations of the Issuer, purchasing additional Shares, selling some or all of the Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing his intention with respect to any and all matters referred to in Item 4 of Schedule 13D, in all cases subject to applicable laws, rules and regulations.

In addition, as a member of the Board, the Reporting Person may receive options or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements for non-employee directors.

Item 5. Interest in Securities of the Issuer.

(a) Based upon the information contained in the Issuer's Proxy Statement filed with the SEC on September 8, 2016, there were 4,150,294 Shares outstanding as of August 26, 2016.

This Amendment No. 2 to Schedule 13D reflects the aggregate number of Shares beneficially owned by the Reporting Person and includes (i) 455,000 Shares owned directly by the Reporting Person; (ii) 1,339,444 Shares issuable upon the exercise of warrants that are currently exercisable (the "Warrants"); and (iii) 11,667 Shares issuable upon the exercise of an option that is exercisable currently (the "Option"). As a result of the foregoing, as of the filing date of this Amendment No. 2 to Schedule 13D, the Reporting Person may be deemed to beneficially own 1,806,111 Shares, or 32.8% of the Shares issued and outstanding as of August 26, 2016. Percent of class assumes the exercise of all of the Warrants and the Option held by the Reporting Person for the acquisition of 1,351,111 Shares.

---

(b) Except as reported in Item 3 above, during the sixty (60) day period on or prior to the date hereof, the Reporting Person has not effected any transaction in the Shares, or securities convertible into, exercisable for or exchangeable for the Shares, by Reporting Person or any person or entity controlled by him, or any person or entity for which he possesses voting or investment control over the securities thereof.

(c) Not applicable.

(d) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

In connection with the Subscription Agreement, the Issuer issued to the Reporting Person 80,000 Shares and a five year warrant to purchase 80,000 Shares at an exercise price of \$4.00 per Share. The Subscription Agreement and warrant are included as exhibits to this Amendment No. 2 to Schedule 13D and are incorporated by reference hereto.

The Reporting Person holds: (i) an option for the purchase of 15,000 Shares that will vest to the extent of 5,000 Shares on each of December 1, 2016, 2017 and 2018; and (ii) an option for the purchase of 35,000 Shares which has vested to the extent of 11,667 Shares and which will vest to the extent of 11,667 Shares on June 10, 2017 and 11,666 Shares on June 10, 2018.

Except as otherwise set forth in Schedule 13D or this Amendment No. 2 to Schedule 13D, there are no contracts, arrangements, understandings or similar relationships existing with respect to the securities of the Issuer between Reporting Person and the Issuer.

Item 7. Material to be filed as exhibits.

Exhibit 7.1 Subscription Agreement, dated September 26, 2016, by and between the Issuer and John M. Desmarais, without exhibits.

Exhibit 7.2 Warrant, dated September 26, 2016, with respect to 80,000 Shares.

This statement on Schedule 13D speaks as of its date, and no inference should be drawn that no change has occurred in the facts set forth herein after the date hereof.

---

SIGNATURE

After reasonable inquiry and to the best of the undersigned's knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

September 28, 2016

By: /s/ John M. Desmarais  
John M. Desmarais

ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).